Magle Chemoswed establishes a manufacturing agreement with Oncopeptides
Magle Chemoswed announces that it has entered into a long-term manufacturing agreement with Oncopeptides, a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases. The agreement comprises commercial manufacturing of the active pharmaceutical substance melflufen HCl (INN melphalan flufenamide) and the intermediate amino dipeptide. Melflufen, is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents inside cancer cells.
The collaboration between Magle Chemoswed and Oncopeptides marks an important step for Magle Chemoswed as a full-service provider, supporting customers to fulfil their needs from early product development to commercialization.
“We are proud that Oncopeptides has chosen Magle Chemoswed as the commercial manufacturer for this exciting product”, says Fredrik Andersson, COO of Magle Chemoswed. “It has been a fruitful collaboration during the development stages, and we look forward to continue working with Oncopeptides to support their success.”
“We are very happy to extend our successful relationship going forward”, says Fredrik Lehmann, Head of Research and CMC at Oncopeptides. “Magle Chemoswed has been a great support during development for many years and we believe they are the ideal partner when we are upgrading our commercial manufacturing.”
Nanexa pausar NEX-18-studien
De måttliga hudreaktioner som uppkommit skiljer sig något från den milda reaktion som normalt uppstår efter administrering av 5-azacitidin. För att klargöra vad detta beror på gör Nanexa tillsammans med klinikerna en utredning inklusive biopsier av den påverkade huden. Utredningen väntas vara klar u...
Nanexa pauses NEX-18 study
The moderate skin reactions that have occured differ slightly from the mild reaction that normally occurs after the administration of 5-azacitidine. To clarify the cause, Nanexa together with the clinics is conducting an investigation including biopsies of the affected skin. The investigation is exp...
Manufacturing of low titer-blood group O whole blood: Presentation of results at the SABM 2021 Annual Meeting
Glycorex Transplantation AB (publ.), listed on NGM Main Regulated Equity, announces thatthe Transfusion unit at the University of Rochester Medical Center presents their experience with the UBP-product for the manufacturing of low titer-blood group O whole blood (LTOWB) attheSociet...
Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies.The company focuses on reducing clinical attritio...